[{"orgOrder":0,"company":"Serina Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"RNA-based Therapeutic","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Serina Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Serina Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"Serina Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Serina Therapeutics","sponsor":"AgeX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"POZ-Apomorphine","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Serina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Serina Therapeutics \/ Serina Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Serina Therapeutics \/ Serina Therapeutics"},{"orgOrder":0,"company":"Serina Therapeutics","sponsor":"Serina Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"POZ-Apomorphine","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Serina Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Serina Therapeutics \/ Serina Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Serina Therapeutics \/ Serina Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Serina Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The combined company will focus on advancing IND-enabling studies of Serina’s lead drug candidate SER-252 (POZ-apomorphine) for treatment of Parkinson’s Disease, and expanding POZ Platform.

                          Brand Name : SER-252

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 15, 2024

                          Lead Product(s) : POZ-Apomorphine

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Recipient : Enable Injections

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The combined company will focus on advancing pre-clinical studies of Serina’s lead drug candidate SER-252 (POZ-apomorphine) for treatment of Parkinson’s Disease, and expanding POZ Platform.

                          Brand Name : SER-252

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 26, 2024

                          Lead Product(s) : POZ-Apomorphine

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Recipient : AgeX Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The agreement provides access to Serina's POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations for RNA-based therapeutics.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          November 17, 2023

                          Lead Product(s) : RNA-based Therapeutic

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Pfizer Inc

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank